Compile Data Set for Download or QSAR
Report error Found 140 Enz. Inhib. hit(s) with all data for entry = 7833
TargetC-X-C chemokine receptor type 4(Human)
Altiris Therapeutics

US Patent
LigandPNGBDBM221860(US9314468, Table 7, Compound 147)
Affinity DataIC50: 1nMT: 2°CAssay Description:Functional modulation of CXCR4 was determined by calcium mobilization assay using leukemic lymphoid CEM cells, which naturally express high levels of...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2017
Entry Details
US Patent

TargetC-X-C chemokine receptor type 4(Human)
Altiris Therapeutics

US Patent
LigandPNGBDBM221760(US9314468, Table 7, Compound 47)
Affinity DataIC50: 1nMT: 2°CAssay Description:Functional modulation of CXCR4 was determined by calcium mobilization assay using leukemic lymphoid CEM cells, which naturally express high levels of...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2017
Entry Details
US Patent

TargetC-X-C chemokine receptor type 4(Human)
Altiris Therapeutics

US Patent
LigandPNGBDBM221857(US9314468, Table 7, Compound 144)
Affinity DataIC50: 4nMT: 2°CAssay Description:Functional modulation of CXCR4 was determined by calcium mobilization assay using leukemic lymphoid CEM cells, which naturally express high levels of...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2017
Entry Details
US Patent

TargetC-X-C chemokine receptor type 4(Human)
Altiris Therapeutics

US Patent
LigandPNGBDBM221796(US9314468, Table 7, Compound 83)
Affinity DataIC50: 4nMT: 2°CAssay Description:Functional modulation of CXCR4 was determined by calcium mobilization assay using leukemic lymphoid CEM cells, which naturally express high levels of...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2017
Entry Details
US Patent

TargetC-X-C chemokine receptor type 4(Human)
Altiris Therapeutics

US Patent
LigandPNGBDBM221834(US9314468, Table 7, Compound 121)
Affinity DataIC50: 4nMT: 2°CAssay Description:Functional modulation of CXCR4 was determined by calcium mobilization assay using leukemic lymphoid CEM cells, which naturally express high levels of...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2017
Entry Details
US Patent

TargetC-X-C chemokine receptor type 4(Human)
Altiris Therapeutics

US Patent
LigandPNGBDBM221854(US9314468, Table 7, Compound 141)
Affinity DataIC50: 5nMT: 2°CAssay Description:Functional modulation of CXCR4 was determined by calcium mobilization assay using leukemic lymphoid CEM cells, which naturally express high levels of...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2017
Entry Details
US Patent

TargetC-X-C chemokine receptor type 4(Human)
Altiris Therapeutics

US Patent
LigandPNGBDBM221864(US9314468, Table 8, Compound 2)
Affinity DataIC50: 5.5nMAssay Description:This assay measures the change in impedance that occurs when cells are stimulated with SDF-1a. Changes in shape and cytoskeleton result in a change o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2017
Entry Details
US Patent

TargetC-X-C chemokine receptor type 4(Human)
Altiris Therapeutics

US Patent
LigandPNGBDBM221865(US9314468, Table 8, Compound 3)
Affinity DataIC50: 5.60nMAssay Description:This assay measures the change in impedance that occurs when cells are stimulated with SDF-1a. Changes in shape and cytoskeleton result in a change o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2017
Entry Details
US Patent

TargetC-X-C chemokine receptor type 4(Human)
Altiris Therapeutics

US Patent
LigandPNGBDBM221863(US9314468, Table 8, Compound 1)
Affinity DataIC50: 5.70nMAssay Description:This assay measures the change in impedance that occurs when cells are stimulated with SDF-1a. Changes in shape and cytoskeleton result in a change o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2017
Entry Details
US Patent

TargetC-X-C chemokine receptor type 4(Human)
Altiris Therapeutics

US Patent
LigandPNGBDBM221866(US9314468, Table 8, Compound 4)
Affinity DataIC50: 5.80nMAssay Description:This assay measures the change in impedance that occurs when cells are stimulated with SDF-1a. Changes in shape and cytoskeleton result in a change o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2017
Entry Details
US Patent

TargetC-X-C chemokine receptor type 4(Human)
Altiris Therapeutics

US Patent
LigandPNGBDBM221808(US9314468, Table 9, Compound 9 | US9314468, Table ...)
Affinity DataIC50: 7nMT: 2°CAssay Description:Functional modulation of CXCR4 was determined by calcium mobilization assay using leukemic lymphoid CEM cells, which naturally express high levels of...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2017
Entry Details
US Patent

TargetC-X-C chemokine receptor type 4(Human)
Altiris Therapeutics

US Patent
LigandPNGBDBM221867(US9314468, Table 8, Compound 5)
Affinity DataIC50: 7.30nMAssay Description:This assay measures the change in impedance that occurs when cells are stimulated with SDF-1a. Changes in shape and cytoskeleton result in a change o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2017
Entry Details
US Patent

TargetC-X-C chemokine receptor type 4(Human)
Altiris Therapeutics

US Patent
LigandPNGBDBM221868(US9314468, Table 8, Compound 6)
Affinity DataIC50: 7.70nMAssay Description:This assay measures the change in impedance that occurs when cells are stimulated with SDF-1a. Changes in shape and cytoskeleton result in a change o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2017
Entry Details
US Patent

TargetC-X-C chemokine receptor type 4(Human)
Altiris Therapeutics

US Patent
LigandPNGBDBM221869(US9314468, Table 8, Compound 7)
Affinity DataIC50: 8.10nMAssay Description:This assay measures the change in impedance that occurs when cells are stimulated with SDF-1a. Changes in shape and cytoskeleton result in a change o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2017
Entry Details
US Patent

TargetC-X-C chemokine receptor type 4(Human)
Altiris Therapeutics

US Patent
LigandPNGBDBM221870(US9314468, Table 8, Compound 8)
Affinity DataIC50: 8.30nMAssay Description:This assay measures the change in impedance that occurs when cells are stimulated with SDF-1a. Changes in shape and cytoskeleton result in a change o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2017
Entry Details
US Patent

TargetC-X-C chemokine receptor type 4(Human)
Altiris Therapeutics

US Patent
LigandPNGBDBM221853(US9314468, Table 7, Compound 140)
Affinity DataIC50: 9nMT: 2°CAssay Description:Functional modulation of CXCR4 was determined by calcium mobilization assay using leukemic lymphoid CEM cells, which naturally express high levels of...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2017
Entry Details
US Patent

TargetC-X-C chemokine receptor type 4(Human)
Altiris Therapeutics

US Patent
LigandPNGBDBM221793(US9314468, Table 7, Compound 80)
Affinity DataIC50: 9nMT: 2°CAssay Description:Functional modulation of CXCR4 was determined by calcium mobilization assay using leukemic lymphoid CEM cells, which naturally express high levels of...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2017
Entry Details
US Patent

TargetC-X-C chemokine receptor type 4(Human)
Altiris Therapeutics

US Patent
LigandPNGBDBM221871(US9314468, Table 9, Compound 12 | US9314468, Table...)
Affinity DataIC50: 9.30nMAssay Description:This assay measures the change in impedance that occurs when cells are stimulated with SDF-1a. Changes in shape and cytoskeleton result in a change o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2017
Entry Details
US Patent

TargetC-X-C chemokine receptor type 4(Human)
Altiris Therapeutics

US Patent
LigandPNGBDBM221872(US9314468, Table 8, Compound 10)
Affinity DataIC50: 9.90nMAssay Description:This assay measures the change in impedance that occurs when cells are stimulated with SDF-1a. Changes in shape and cytoskeleton result in a change o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2017
Entry Details
US Patent

TargetC-X-C chemokine receptor type 4(Human)
Altiris Therapeutics

US Patent
LigandPNGBDBM221738(US9314468, Table 7, Compound 25)
Affinity DataIC50: 10nMT: 2°CAssay Description:Functional modulation of CXCR4 was determined by calcium mobilization assay using leukemic lymphoid CEM cells, which naturally express high levels of...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2017
Entry Details
US Patent

TargetC-X-C chemokine receptor type 4(Human)
Altiris Therapeutics

US Patent
LigandPNGBDBM221800(US9314468, Table 7, Compound 87)
Affinity DataIC50: 11nMT: 2°CAssay Description:Functional modulation of CXCR4 was determined by calcium mobilization assay using leukemic lymphoid CEM cells, which naturally express high levels of...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2017
Entry Details
US Patent

TargetC-X-C chemokine receptor type 4(Human)
Altiris Therapeutics

US Patent
LigandPNGBDBM221873(US9314468, Table 8, Compound 11)
Affinity DataIC50: 11nMAssay Description:This assay measures the change in impedance that occurs when cells are stimulated with SDF-1a. Changes in shape and cytoskeleton result in a change o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2017
Entry Details
US Patent

TargetC-X-C chemokine receptor type 4(Human)
Altiris Therapeutics

US Patent
LigandPNGBDBM221875(US9314468, Table 8, Compound 13)
Affinity DataIC50: 12nMAssay Description:This assay measures the change in impedance that occurs when cells are stimulated with SDF-1a. Changes in shape and cytoskeleton result in a change o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2017
Entry Details
US Patent

TargetC-X-C chemokine receptor type 4(Human)
Altiris Therapeutics

US Patent
LigandPNGBDBM221874(US9314468, Table 8, Compound 12 | US9314468, Table...)
Affinity DataIC50: 12nMAssay Description:This assay measures the change in impedance that occurs when cells are stimulated with SDF-1a. Changes in shape and cytoskeleton result in a change o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2017
Entry Details
US Patent

TargetC-X-C chemokine receptor type 4(Human)
Altiris Therapeutics

US Patent
LigandPNGBDBM221876(US9314468, Table 8, Compound 14 | US9314468, Table...)
Affinity DataIC50: 12nMAssay Description:This assay measures the change in impedance that occurs when cells are stimulated with SDF-1a. Changes in shape and cytoskeleton result in a change o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2017
Entry Details
US Patent

TargetC-X-C chemokine receptor type 4(Human)
Altiris Therapeutics

US Patent
LigandPNGBDBM221761(US9314468, Table 9, Compound 1 | US9314468, Table ...)
Affinity DataIC50: 12nMT: 2°CAssay Description:Functional modulation of CXCR4 was determined by calcium mobilization assay using leukemic lymphoid CEM cells, which naturally express high levels of...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2017
Entry Details
US Patent

TargetC-X-C chemokine receptor type 4(Human)
Altiris Therapeutics

US Patent
LigandPNGBDBM221832(US9314468, Table 7, Compound 119)
Affinity DataIC50: 13nMT: 2°CAssay Description:Functional modulation of CXCR4 was determined by calcium mobilization assay using leukemic lymphoid CEM cells, which naturally express high levels of...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2017
Entry Details
US Patent

TargetC-X-C chemokine receptor type 4(Human)
Altiris Therapeutics

US Patent
LigandPNGBDBM221858(US9314468, Table 7, Compound 145)
Affinity DataIC50: 14nMT: 2°CAssay Description:Functional modulation of CXCR4 was determined by calcium mobilization assay using leukemic lymphoid CEM cells, which naturally express high levels of...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2017
Entry Details
US Patent

TargetC-X-C chemokine receptor type 4(Human)
Altiris Therapeutics

US Patent
LigandPNGBDBM221877(US9314468, Table 8, Compound 15)
Affinity DataIC50: 15nMAssay Description:This assay measures the change in impedance that occurs when cells are stimulated with SDF-1a. Changes in shape and cytoskeleton result in a change o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2017
Entry Details
US Patent

TargetC-X-C chemokine receptor type 4(Human)
Altiris Therapeutics

US Patent
LigandPNGBDBM221783(US9314468, Table 9, Compound 4 | US9314468, Table ...)
Affinity DataIC50: 15nMT: 2°CAssay Description:Functional modulation of CXCR4 was determined by calcium mobilization assay using leukemic lymphoid CEM cells, which naturally express high levels of...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2017
Entry Details
US Patent

TargetC-X-C chemokine receptor type 4(Human)
Altiris Therapeutics

US Patent
LigandPNGBDBM221775(US9314468, Table 7, Compound 62)
Affinity DataIC50: 15nMT: 2°CAssay Description:Functional modulation of CXCR4 was determined by calcium mobilization assay using leukemic lymphoid CEM cells, which naturally express high levels of...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2017
Entry Details
US Patent

TargetC-X-C chemokine receptor type 4(Human)
Altiris Therapeutics

US Patent
LigandPNGBDBM221783(US9314468, Table 9, Compound 4 | US9314468, Table ...)
Affinity DataIC50: 16nMT: 2°CAssay Description:Functional modulation of CXCR4 was determined by calcium mobilization assay using leukemic lymphoid CEM cells, which naturally express high levels of...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2017
Entry Details
US Patent

TargetC-X-C chemokine receptor type 4(Human)
Altiris Therapeutics

US Patent
LigandPNGBDBM221825(US9314468, Table 9, Compound 14 | US9314468, Table...)
Affinity DataIC50: 17nMT: 2°CAssay Description:Functional modulation of CXCR4 was determined by calcium mobilization assay using leukemic lymphoid CEM cells, which naturally express high levels of...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2017
Entry Details
US Patent

TargetC-X-C chemokine receptor type 4(Human)
Altiris Therapeutics

US Patent
LigandPNGBDBM221825(US9314468, Table 9, Compound 14 | US9314468, Table...)
Affinity DataIC50: 18nMT: 2°CAssay Description:Functional modulation of CXCR4 was determined by calcium mobilization assay using leukemic lymphoid CEM cells, which naturally express high levels of...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2017
Entry Details
US Patent

TargetC-X-C chemokine receptor type 4(Human)
Altiris Therapeutics

US Patent
LigandPNGBDBM221740(US9314468, Table 7, Compound 27)
Affinity DataIC50: 18nMT: 2°CAssay Description:Functional modulation of CXCR4 was determined by calcium mobilization assay using leukemic lymphoid CEM cells, which naturally express high levels of...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2017
Entry Details
US Patent

TargetC-X-C chemokine receptor type 4(Human)
Altiris Therapeutics

US Patent
LigandPNGBDBM221856(US9314468, Table 7, Compound 143)
Affinity DataIC50: 20nMT: 2°CAssay Description:Functional modulation of CXCR4 was determined by calcium mobilization assay using leukemic lymphoid CEM cells, which naturally express high levels of...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2017
Entry Details
US Patent

TargetC-X-C chemokine receptor type 4(Human)
Altiris Therapeutics

US Patent
LigandPNGBDBM221851(US9314468, Table 7, Compound 138)
Affinity DataIC50: 20nMT: 2°CAssay Description:Functional modulation of CXCR4 was determined by calcium mobilization assay using leukemic lymphoid CEM cells, which naturally express high levels of...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2017
Entry Details
US Patent

TargetC-X-C chemokine receptor type 4(Human)
Altiris Therapeutics

US Patent
LigandPNGBDBM221808(US9314468, Table 9, Compound 9 | US9314468, Table ...)
Affinity DataIC50: 21nMT: 2°CAssay Description:Functional modulation of CXCR4 was determined by calcium mobilization assay using leukemic lymphoid CEM cells, which naturally express high levels of...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2017
Entry Details
US Patent

TargetC-X-C chemokine receptor type 4(Human)
Altiris Therapeutics

US Patent
LigandPNGBDBM221827(US9314468, Table 7, Compound 114)
Affinity DataIC50: 21nMT: 2°CAssay Description:Functional modulation of CXCR4 was determined by calcium mobilization assay using leukemic lymphoid CEM cells, which naturally express high levels of...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2017
Entry Details
US Patent

TargetC-X-C chemokine receptor type 4(Human)
Altiris Therapeutics

US Patent
LigandPNGBDBM221744(US9314468, Table 7, Compound 31)
Affinity DataIC50: 22nMT: 2°CAssay Description:Functional modulation of CXCR4 was determined by calcium mobilization assay using leukemic lymphoid CEM cells, which naturally express high levels of...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2017
Entry Details
US Patent

TargetC-X-C chemokine receptor type 4(Human)
Altiris Therapeutics

US Patent
LigandPNGBDBM221769(US9314468, Table 9, Compound 2 | US9314468, Table ...)
Affinity DataIC50: 22nMT: 2°CAssay Description:Functional modulation of CXCR4 was determined by calcium mobilization assay using leukemic lymphoid CEM cells, which naturally express high levels of...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2017
Entry Details
US Patent

TargetC-X-C chemokine receptor type 4(Human)
Altiris Therapeutics

US Patent
LigandPNGBDBM221769(US9314468, Table 9, Compound 2 | US9314468, Table ...)
Affinity DataIC50: 22nMT: 2°CAssay Description:Functional modulation of CXCR4 was determined by calcium mobilization assay using leukemic lymphoid CEM cells, which naturally express high levels of...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2017
Entry Details
US Patent

TargetC-X-C chemokine receptor type 4(Human)
Altiris Therapeutics

US Patent
LigandPNGBDBM221871(US9314468, Table 9, Compound 12 | US9314468, Table...)
Affinity DataIC50: 24nMT: 2°CAssay Description:Functional modulation of CXCR4 was determined by calcium mobilization assay using leukemic lymphoid CEM cells, which naturally express high levels of...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2017
Entry Details
US Patent

TargetC-X-C chemokine receptor type 4(Human)
Altiris Therapeutics

US Patent
LigandPNGBDBM221819(US9314468, Table 7, Compound 106)
Affinity DataIC50: 24nMT: 2°CAssay Description:Functional modulation of CXCR4 was determined by calcium mobilization assay using leukemic lymphoid CEM cells, which naturally express high levels of...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2017
Entry Details
US Patent

TargetC-X-C chemokine receptor type 4(Human)
Altiris Therapeutics

US Patent
LigandPNGBDBM221840(US9314468, Table 7, Compound 127)
Affinity DataIC50: 26nMT: 2°CAssay Description:Functional modulation of CXCR4 was determined by calcium mobilization assay using leukemic lymphoid CEM cells, which naturally express high levels of...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2017
Entry Details
US Patent

TargetC-X-C chemokine receptor type 4(Human)
Altiris Therapeutics

US Patent
LigandPNGBDBM221878(US9314468, Table 8, Compound 16)
Affinity DataIC50: 26nMAssay Description:This assay measures the change in impedance that occurs when cells are stimulated with SDF-1a. Changes in shape and cytoskeleton result in a change o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2017
Entry Details
US Patent

TargetC-X-C chemokine receptor type 4(Human)
Altiris Therapeutics

US Patent
LigandPNGBDBM221785(US9314468, Table 9, Compound 5 | US9314468, Table ...)
Affinity DataIC50: 30nMT: 2°CAssay Description:Functional modulation of CXCR4 was determined by calcium mobilization assay using leukemic lymphoid CEM cells, which naturally express high levels of...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2017
Entry Details
US Patent

TargetC-X-C chemokine receptor type 4(Human)
Altiris Therapeutics

US Patent
LigandPNGBDBM221755(US9314468, Table 7, Compound 42)
Affinity DataIC50: 30nMT: 2°CAssay Description:Functional modulation of CXCR4 was determined by calcium mobilization assay using leukemic lymphoid CEM cells, which naturally express high levels of...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2017
Entry Details
US Patent

TargetC-X-C chemokine receptor type 4(Human)
Altiris Therapeutics

US Patent
LigandPNGBDBM221785(US9314468, Table 9, Compound 5 | US9314468, Table ...)
Affinity DataIC50: 30nMT: 2°CAssay Description:Functional modulation of CXCR4 was determined by calcium mobilization assay using leukemic lymphoid CEM cells, which naturally express high levels of...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2017
Entry Details
US Patent

TargetC-X-C chemokine receptor type 4(Human)
Altiris Therapeutics

US Patent
LigandPNGBDBM221848(US9314468, Table 7, Compound 135)
Affinity DataIC50: 30nMT: 2°CAssay Description:Functional modulation of CXCR4 was determined by calcium mobilization assay using leukemic lymphoid CEM cells, which naturally express high levels of...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2017
Entry Details
US Patent

Displayed 1 to 50 (of 140 total ) | Next | Last >>
Jump to: